EUCTR2010-022492-54-IT进行中（未招募）不适用
Fixed Dose Combination Drug (FDC) for Secondary Cardiovascular Prevention. Improving equitable access and adherence to secondary Prevention therapy with a Fixed-Dose Combination Drug - FOCUS
Centro Nacional de Investigaciones Cardiovasculares (CNIC)0 个研究点目标入组 1,340 人开始时间: 2011年2月22日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All patients, male and female, 40 years of age or older, with a history of ST-elevation MI within the last 2 years, attending any of the selected sites and signing the consent Patients in whom secondary prevention with aspirin, statin and ACE-inhibitors is indicated.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with: secondary dyslipemia; in which any of the components of the FDC is contraindicated; living in a nursing home or with mental illness limiting the capacity of self care or participating in another trial; with previous percutaneous transluminal coronary angioplasty (PTCA) with a drug eluting stent (DES) whitin the last year; with severe congestive heart failure (NYHA III-IV); with serum creatinine >2 mg/dl; with any condition limiting life expectancy (<2years); pregnant or premenopausal women
研究者
相似试验
招募中
2 期
ASSESSMENT OF A NOVEL FIXED DOSE COMBINATION (FDC) DRUG VR-AD-1005 FOR THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHOLERA: A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLINDED EFFICACY AND SAFETY TRIAPACTR202106780884401Vanessa Research Holdings Inc.300
进行中（未招募）
1 期
Efficacy and safety of products containing trazodone and gabapentin in patients affected by painful diabeticneuropathy.Painful diabetic neuropathyMedDRA version: 20.0Level: LLTClassification code 10012683Term: Diabetic peripheral neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10012680Term: Diabetic neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10014698Term: Endocrine disordersSystem Organ Class: 10014698 - Endocrine disordersEUCTR2018-000133-12-CZAngelini S.p.A.240
进行中（未招募）
1 期
Efficacy and safety of products containing trazodone and gabapentin in patients affected by painful diabeticneuropathy.Painful diabetic neuropathyMedDRA version: 20.0Level: LLTClassification code 10012683Term: Diabetic peripheral neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10012680Term: Diabetic neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10014698Term: Endocrine disordersSystem Organ Class: 10014698 - Endocrine disordersEUCTR2018-000133-12-GBAngelini S.p.A.240
进行中（未招募）
1 期
Efficacy and safety of products containing trazodone and gabapentin in patients affected by painful diabetic neuropathy.Painful diabetic neuropathyMedDRA version: 21.1Level: LLTClassification code 10012683Term: Diabetic peripheral neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10012680Term: Diabetic neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10014698Term: Endocrine disordersSystem Organ Class: 10014698 - Endocrine disordersEUCTR2018-000133-12-PLAngelini S.p.A.240
已完成
3 期
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsHIV-1 InfectionNCT02607956Gilead Sciences657